NICE recommends ixekizumab for persistent severe plaque psoriasisBMJ 2017; 356 doi: https://doi.org/10.1136/bmj.j1275 (Published 13 March 2017) Cite this as: BMJ 2017;356:j1275
- Susan Mayor
The National Institute for Health and Care Excellence (NICE), in its final draft guidance issued this week, has recommended ixekizumab, an antibody that inhibits interleukin-17A, as an option for treating adults with severe plaque psoriasis that doesn’t respond to standard therapies.
The guidance recommended ixekizumab as an option for treating plaque psoriasis in adults, but only if they had severe disease (a …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial